Share this article on:

Mitochondrial Haplogroups Are Associated With Clinical Pattern of AIDS Progression in HIV-Infected Patients

Guzmán-Fulgencio, María PhD*; Jiménez, José Luis PhD; García-Álvarez, Mónica PhD*; Bellón, José María BSc; Fernández-Rodriguez, Amanda PhD*; Campos, Yolanda PhD§; Rodríguez, Carmen PhD; González-Garcia, Juan MD, PhD; Riera, Melchor MD, PhD#; Viciana, Pompeyo MD, PhD**; Muñoz-Fernández, MÁngeles PhD††,‡‡,§§ª; Resino, Salvador PhD*

JAIDS Journal of Acquired Immune Deficiency Syndromes: June 1st, 2013 - Volume 63 - Issue 2 - p 178–183
doi: 10.1097/QAI.0b013e3182893f74
Brief Report: Basic and Translational Science

Abstract: We performed a cross-sectional study in 469 HIV-infected patients, whose mitochondrial haplogroups were genotyped to study their association with the clinical pattern of AIDS progression. The chance of not having an AIDS progression was 1.45 [95% of confidence interval (CI) = 1.02 to 2.05, P = 0.035) times greater in patients with cluster HV and 1.51 (95% CI = 1.06 to 2.18, P = 0.021) times greater in patients with haplogroup H. However, we only found significant values for haplogroup H (odds ratio = 1.52, 95% CI = 1.01 to 2.32, P = 0.049) in an ordinal logistic regression adjusted by gender, age at HIV infection, intravenous drug users, and hepatitis C virus infection. These data suggest that mitochondrial haplogroups might play a significant role in AIDS progression.

*Unidad de Coinfección HIV/Hepatitis, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain;

Plataforma de Laboratorio, and the

Fundación para la Investigación Biomédica, Hospital General Universitario “Gregorio Marañón,” Madrid, Spain;

§Unidad de Patología Mitocondrial, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain;

Centro Sanitario Sandoval, Madrid, Spain;

Servicio de Medicina Interna, Hospital Universitario “La Paz,” Madrid, Spain;

#Servicio de Medicina Interna-Infecciosas, Hospital Universitario “Son Espases,” Palma de Mallorca, Spain;

**Servicio de Enfermedades Infecciosas, Hospital Virgen del Rocío, Seville, Spain;

††Laboratorio de Inmuno-biología Molecular, Hospital General Universitario “Gregorio Marañón,” Madrid, Spain;

‡‡Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain; and

§§Unidad de Retrovirlogía Humana, HGUGM-CSIC, Madrid, Spain.

Correspondence to: Salvador Resino, PhD, Unidad de Coinfección HIV/Hepatitis, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Carretera Majadahonda-Pozuelo, Km 2.2, 28220 Majadahonda, Madrid, Spain (e-mail: sresino@isciii.es).

Supported by grants from the “Instituto de Salud Carlos III” (PI08/0738 and PI11/00245 to S.R., PI09/2341 to Y.C., RD09/0076/00103 and RD06-0006-0035 to M.A.M.-F., and PI11-00888 to J.L.J.), “Fundación para la Investigación y la Prevención del Sida en España” (240800/09 and 300509 to M.A.M.-F.), Fundación Alicia Koplowitz (2008 to Y.C.), Fundación Caja Navarra, Comunidad de Madrid (S-SAL-0159-2006 to M.A.M.-F. and S-2010/BMD2351 to J.L.J.), “Programa de Investigacion de la Consejeria de Sanidad de la Comunidad de Madrid” to J. L. Jiménez, “Instituto de Salud Carlos III” (UIPY-1377/08, CM09/00031, CM08/00101, and CM10/00105, respectively, A.F.-R., M.G.-F., M.G.-A., and M.A.J.S.).

The authors have no conflicts of interest to disclose.

C.R., J.G-G., and M.R.: on behalf of CoRIS and the HIV Biobank integrated in the RIS. P.V.: on behalf of LTNPs Cohort integrated in the RIS.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).

Received November 09, 2012

Accepted January 22, 2013

© 2013 by Lippincott Williams & Wilkins